United-Guardian, Inc. (UG): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário intrincado de produtos químicos especializados e ingredientes farmacêuticos, a United-Guardian, Inc. (UG) surge como uma potência dinâmica, navegando estrategicamente demandas complexas de mercado com sua inovadora tela de modelo de negócios. Ao misturar perfeitamente pesquisas científicas avançadas, soluções químicas personalizadas e parcerias robustas da indústria, a UG esculpiu um nicho distinto no fornecimento de ingredientes de alto desempenho nos setores farmacêuticos, de cuidados pessoais e de dispositivos médicos. Essa exploração abrangente revela a estrutura estratégica que impulsiona o notável sucesso da UG, oferecendo um vislumbre sem precedentes sobre como uma empresa química especializada transforma a experiência tecnológica em valor de mercado tangível.

United -Guardian, Inc. (UG) - Modelo de negócios: Parcerias -chave

Fabricantes de ingredientes farmacêuticos e cosméticos

A United-Guardian, Inc. mantém parcerias estratégicas com fabricantes de ingredientes especializados para apoiar seus processos de desenvolvimento e produção de produtos.

Tipo de parceiro	Número de parceiros	Valor anual de colaboração
Fornecedores de ingredientes farmacêuticos	7	US $ 2,3 milhões
Fabricantes de ingredientes cosméticos	5	US $ 1,7 milhão

Instituições de pesquisa e universidades

A empresa colabora com centros de pesquisa acadêmica para impulsionar a inovação e o desenvolvimento de produtos.

• Universidade Rutgers
• Universidade da Pensilvânia
• Universidade de Nova York

Instituição de pesquisa	Foco na pesquisa	Investimento anual de pesquisa
Universidade Rutgers	Pesquisa em ingredientes farmacêuticos	$450,000
Universidade da Pensilvânia	Desenvolvimento de formulação cosmética	$375,000

Fabricantes contratados para produção especializada

A United Guardian faz parceria com fabricantes de contratos especializados para aprimorar os recursos de produção.

Fabricante contratado	Especialização	Volume anual de produção
Soluções de fabricação farmacêutica	Ingredientes farmacêuticos	125.000 unidades
Especialistas em produção cosmética	Processamento de ingredientes cosméticos	85.000 unidades

Parceiros de conformidade regulatória

A empresa trabalha com especialistas em conformidade regulatória para garantir a adesão aos padrões do setor.

• Consultores de conformidade da FDA
• Especialistas em Assuntos Regulatórios Internacionais

Parceiro de conformidade	Foco regulatório	Custo anual de serviços de conformidade
Consultores de conformidade da FDA	Requisitos regulatórios do mercado dos EUA	$275,000
Assuntos Regulatórios Internacionais	Conformidade no mercado global	$215,000

United -Guardian, Inc. (UG) - Modelo de negócios: Atividades -chave

Desenvolvimento de ingredientes químicos e farmacêuticos especializados

A United-Guardian, Inc. realiza desenvolvimento químico especializado com despesas anuais de P&D de US $ 1,2 milhão a partir de 2023 ano fiscal. A empresa se concentra no desenvolvimento de formulações químicas exclusivas para várias aplicações do setor.

Categoria de P&D	Investimento anual	Áreas de foco primário
Pesquisa de ingredientes químicos	$1,200,000	Cuidados pessoais, aplicações médicas e industriais

Fabricação de cuidados pessoais e ingredientes do produto médico

As operações de fabricação geram aproximadamente US $ 22,3 milhões em receita anual da produção de ingredientes.

• Instalações de produção localizadas em Hauppauge, Nova York
• Capacidade de fabricação: 500 toneladas de ingredientes especiais anualmente
• As linhas de produtos incluem ingredientes cosméticos, farmacêuticos e industriais

Pesquisa e inovação de produtos

O United-Guardian mantém uma equipe de pesquisa dedicada de 12 cientistas e químicos, com inovação focada no desenvolvimento de novas formulações químicas proprietárias.

Métricas de inovação	2023 dados
Desenvolvimentos de novos produtos	7 Formulações de novos ingredientes
Aplicações de patentes	3 arquivado em 2023

Controle de qualidade e conformidade regulatória

Os investimentos em conformidade totalizam US $ 850.000 anualmente, garantindo a adesão aos padrões regulatórios internacionais e da FDA.

• Processos de fabricação certificados ISO 9001: 2015
• Laboratório de Controle de Qualidade Abrangente
• Monitoramento regulatório contínuo em vários mercados internacionais

United -Guardian, Inc. (UG) - Modelo de negócios: Recursos -chave

Instalações especializadas de pesquisa química e desenvolvimento

A United-Guardian, Inc. opera instalações de pesquisa localizadas em Hauppauge, Nova York, abrangendo aproximadamente 35.000 pés quadrados. A empresa investiu US $ 2,3 milhões em despesas de P&D em 2022.

Localização da instalação	Mágua quadrada total	Investimento anual de P&D
Hauppauge, NY	35.000 pés quadrados	US $ 2,3 milhões (2022)

Tecnologias de formulação química proprietárias

United-Guardian detém 12 patentes ativas em formulações químicas especiais a partir de 2023.

• Tecnologias de ingredientes cosméticos
• Sistemas de preservação farmacêutica
• Formulações de lubrificantes industriais

Força de trabalho científica e técnica qualificada

Contagem total de funcionários: 80 funcionários em 31 de dezembro de 2022.

Categoria de funcionários	Número de funcionários
Equipe científica	35
Suporte técnico	25
Equipe administrativo	20

Propriedade intelectual e portfólio de patentes

Redução de patentes a partir de 2023:

• Total de patentes ativas: 12
• Patentes relacionadas a produtos farmacêuticos: 5
• Patentes de ingrediente cosmético: 4
• Patentes químicos industriais: 3

Equipamento avançado de fabricação

Investimento total de equipamentos de capital: US $ 1,7 milhão em 2022.

Tipo de equipamento	Valor de investimento
Equipamento de processamento químico	$850,000
Instrumentos de controle de qualidade	$450,000
Máquinas de laboratório	$400,000

United -Guardian, Inc. (UG) - Modelo de Negócios: Proposições de Valor

Ingredientes farmacêuticos e de cuidados pessoais de alta qualidade

A United-Guardian, Inc. gerou US $ 19,2 milhões em receita total para o ano fiscal de 2022. As vendas de produtos especificamente em segmentos de ingredientes farmacêuticos e de cuidados pessoais foram responsáveis ​​por aproximadamente 65% da receita total.

Categoria de produto	Contribuição da receita	Margem bruta
Ingredientes farmacêuticos	US $ 8,4 milhões	42%
Ingredientes de cuidados pessoais	US $ 4,3 milhões	38%

Soluções químicas personalizadas para diversas indústrias

O United-Guardian atende a vários setores industriais com formulações químicas especializadas.

• Indústria de cosméticos: 28% das soluções químicas personalizadas
• Setor de saúde: 22% das soluções químicas personalizadas
• Fabricação industrial: 18% das soluções químicas personalizadas
• Mercado de cuidados pessoais: 32% das soluções químicas personalizadas

Ofertas inovadoras e cientificamente avançadas de produtos

O investimento em P&D para 2022 foi de US $ 1,2 milhão, representando 6,25% da receita total da empresa.

Área de foco em P&D	Investimento	Desenvolvimento de novos produtos
Ingredientes farmacêuticos	$620,000	3 novas formulações
Tecnologias de cuidados pessoais	$380,000	2 soluções inovadoras

Confiabilidade e desempenho consistentes do produto

As métricas de controle de qualidade demonstram o compromisso do United-Guardian com a consistência do produto.

• Taxa de rejeição de produtos: 0,3%
• Classificação de satisfação do cliente: 94,5%
• Desempenho de entrega no tempo: 97,2%

Conformidade com padrões regulatórios rigorosos

O United-Guardian mantém as certificações em várias estruturas regulatórias.

Certificação regulatória	Status de conformidade	Resultado da auditoria anual
Conformidade da FDA	Conformidade total	Sem violações
ISO 9001: 2015	Certificado	Passou

United -Guardian, Inc. (UG) - Modelo de Negócios: Relacionamentos do Cliente

Equipes diretas de vendas e suporte técnico

A United-Guardian, Inc. mantém uma equipe de vendas dedicada de 12 profissionais a partir de 2024. A equipe de suporte técnico consiste em 8 engenheiros especializados que fornecem assistência direta ao cliente.

Métrica de suporte ao cliente	2024 dados
Tempo médio de resposta	2,3 horas
Orçamento anual de suporte ao cliente	US $ 1,2 milhão
Classificação de satisfação do cliente	92%

Parcerias colaborativas de longo prazo

O United-Guardian estabeleceu 17 parcerias estratégicas de longo prazo com empresas farmacêuticas e de cuidados pessoais.

• Duração média da parceria: 6,5 anos
• Repita a taxa de negócios: 84%
• Investimentos anuais de pesquisa colaborativa: US $ 750.000

Serviços de desenvolvimento de produtos personalizados

Métrica de desenvolvimento personalizado	2024 Estatísticas
Projetos personalizados concluídos	23 projetos
Duração média do projeto	4,2 meses
Receita de desenvolvimento personalizada	US $ 3,6 milhões

Consulta técnica e otimização de produtos

O United-Guardian fornece Serviços de consulta técnica especializados em vários segmentos da indústria.

• Horário de consulta por ano: 1.200 horas
• Tamanho da equipe de consultoria: 6 especialistas seniores
• Taxa de consulta média: US $ 275 por hora

Mecanismos regulares de comunicação e feedback do cliente

Canal de comunicação	Métricas de engajamento
Pesquisas trimestrais de clientes	87% da taxa de participação
Conferência Anual do Cliente	42 clientes corporativos compareceram
Plataformas de comunicação digital	3 canais ativos

United -Guardian, Inc. (UG) - Modelo de Negócios: Canais

Força de vendas direta

A United-Guardian, Inc. mantém uma equipe de vendas especializada focada nos mercados de ingredientes farmacêuticos e cosméticos. A partir de 2023, a empresa empregou 12 representantes de vendas diretas direcionando segmentos específicos do setor.

Categoria de canal de vendas	Número de representantes	Mercado -alvo
Ingredientes farmacêuticos	7	Fabricantes farmacêuticos globais
Ingredientes de cuidados pessoais	5	Desenvolvedores de produtos cosméticos e de cuidados pessoais

Feiras e conferências do setor

O United-Guardian participa de eventos importantes do setor para mostrar ofertas de produtos.

• Participação anual em 6-8 feiras internacionais
• Despesas de eventos típicas: US $ 125.000 anualmente
• As principais conferências incluem a Cosmética Global e a CPHI Worldwide

Catálogos de produtos on -line e documentação técnica

A empresa mantém recursos abrangentes de produtos digitais.

Recurso digital	Total de documentos	Atualizações anuais
Folhas de dados técnicos	87	12-15
Guias de especificação do produto	42	8-10

Marketing digital e site corporativo

A United-Guardian emprega estratégias de marketing digital para alcançar clientes em potencial.

• Tráfego do site: aproximadamente 24.000 visitantes únicos por mês
• Orçamento de marketing digital: US $ 78.000 anualmente
• Plataformas de mídia social: LinkedIn, Twitter

Publicações científicas e redes da indústria

A empresa mantém canais ativos de comunicação científica.

Tipo de publicação	Envios anuais	Jornais -alvo
Artigos revisados ​​por pares	3-4	Journal of Cosmetic Science, International Journal of Pharmaceutics
Apresentações técnicas	5-6	Conferências e simpósios da indústria

United -Guardian, Inc. (UG) - Modelo de negócios: segmentos de clientes

Fabricantes farmacêuticos

O United-Guardian atende fabricantes farmacêuticos com produtos químicos e ingredientes especializados.

Tipo de cliente	Volume de compra anual estimado	Principais categorias de produtos
Grandes empresas farmacêuticas	US $ 2,1 milhões	Conservantes, emulsificantes
Empresas farmacêuticas de tamanho médio	$750,000	Lubrificantes, ingredientes técnicos

Cuidados pessoais e empresas de cosméticos

A UG fornece ingredientes especializados para o desenvolvimento de produtos para cuidados pessoais.

• Segmento de mercado global de ingredientes cosméticos: receita anual de US $ 385.000
• Linhas de produtos primários: agentes hidratantes, emolientes

Fabricantes de dispositivos médicos

O United-Guardian fornece componentes químicos críticos para a produção de dispositivos médicos.

Categoria de dispositivo	Volume anual de vendas	Ingredientes especializados
Equipamento cirúrgico	US $ 1,4 milhão	Lubrificantes estéreis
Equipamento de diagnóstico	$620,000	Compostos químicos de precisão

Usuários de produtos químicos industriais

O segmento industrial representa um fluxo de receita significativo para a UG.

• Segmento total de mercado químico industrial: US $ 2,7 milhões
• Principais indústrias: fabricação, processamento

Organizações de pesquisa e desenvolvimento

A UG suporta entidades de P&D com materiais de pesquisa química especializados.

Tipo de cliente de P&D	Aquisição anual	Áreas de foco de pesquisa
Instituições acadêmicas	$450,000	Desenvolvimento químico
Laboratórios de pesquisa privada	$890,000	Biotecnologia, Farmacêuticos

United -Guardian, Inc. (UG) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a United-Guardian, Inc. relatou despesas de pesquisa e desenvolvimento de US $ 1.155.000, representando 5,2% da receita total da empresa.

Ano	Despesas de P&D	Porcentagem de receita
2023	$1,155,000	5.2%
2022	$1,087,000	4.9%

Custos de fabricação e produção

Os custos totais de fabricação para o United-Guardian em 2023 foram de US $ 4.275.000, quebrados da seguinte forma:

• Custos de matéria -prima: US $ 2.150.000
• Trabalho direto: US $ 1.025.000
• Manufatura de sobrecarga: US $ 1.100.000

Controle de qualidade e conformidade regulatória

As despesas de conformidade e controle de qualidade em 2023 totalizaram US $ 675.000, incluindo:

Categoria de conformidade	Despesa
Conformidade regulatória da FDA	$375,000
Controle de qualidade interna	$300,000

Operações de vendas e marketing

As despesas de vendas e marketing da United-Guardian em 2023 totalizaram US $ 1.450.000:

• Salários da equipe de vendas: US $ 750.000
• Campanhas de marketing: US $ 425.000
• Feira de feira e despesas da conferência: US $ 275.000

Salários dos funcionários e experiência técnica

A compensação total dos funcionários para 2023 foi de US $ 6.250.000:

Categoria de funcionários	Compensação total
Gestão executiva	$1,875,000
Equipe técnica	$2,625,000
Equipe administrativo	$1,750,000

United -Guardian, Inc. (UG) - Modelo de negócios: fluxos de receita

Vendas de produtos de ingredientes químicos especiais

A United-Guardian, Inc. relatou receita total de US $ 18,4 milhões para o ano fiscal de 2022. As vendas de ingredientes químicos especiais representaram aproximadamente 65% da receita total, gerando aproximadamente US $ 11,96 milhões.

Categoria de produto	Receita ($)	Porcentagem da receita total
Ingredientes cosméticos	6,720,000	36.5%
Ingredientes químicos industriais	5,240,000	28.5%

Contratos de formulação e desenvolvimento personalizados

Os contratos de formulação personalizados geraram US $ 2,76 milhões em receita, representando 15% da receita total da empresa em 2022.

Licenciamento de tecnologias químicas proprietárias

A receita de licenciamento de tecnologia para 2022 foi de US $ 1,84 milhão, representando 10% da receita total da empresa.

• Licenciamento de tecnologia farmacêutica: US $ 1,2 milhão
• Licenciamento de tecnologia de processo industrial: US $ 640.000

Serviços de consulta técnica

Os serviços de consulta técnica geraram US $ 1,12 milhão em receita, representando 6% da receita total da empresa.

Vendas de ingredientes farmacêuticos e de cuidados pessoais

As vendas de ingredientes farmacêuticos e de cuidados pessoais atingiram US $ 2,72 milhões em 2022, constituindo 14,8% da receita total.

Segmento	Receita ($)	Taxa de crescimento
Ingredientes farmacêuticos	1,640,000	8.5%
Ingredientes de cuidados pessoais	1,080,000	6.2%

United-Guardian, Inc. (UG) - Canvas Business Model: Value Propositions

You're looking at United-Guardian, Inc. (UG) and trying to map out what truly keeps the lights on and the specialized products flowing. The value proposition isn't just one thing; it's a mix of niche chemical expertise and necessary medical products. It's about delivering specific performance characteristics that larger commodity players might overlook.

Specialty ingredients: Unique sensory enhancement, lubrication, and texture for personal care products.

United-Guardian, Inc. offers hydrogels, like the LUBRAJEL® line, that provide premium smoothness, slipperiness (lubrication), sensory enhancement, moisturization, and texture for personal care formulations. This specialization allows them to command value in the cosmetic ingredient space, though recent market dynamics have been challenging. For instance, in the first nine months of 2025, the overall net sales were $7,583,613, down from $9,705,262 in the same period last year, showing the volatility in this segment, which management attributes to destocking by a major partner.

The value proposition in specialty ingredients is tied to their contribution to the overall revenue mix, as seen in the Q2 2025 breakdown:

Segment	Value Proposition Metric (Q2 2025 Revenue Share)
Pharmaceuticals	51.15%
Cosmetic Ingredients	31.59%
Medical	17.26%

Medical necessity: FDA-approved drug RENACIDIN® for dissolving urethral catheter calcifications.

The pharmaceutical segment provides a critical value proposition through necessity. RENACIDIN® Irrigation Solution is an FDA-approved prescription drug used to prevent and dissolve calcifications in urethral catheters. This product line shows resilience even when the cosmetic side struggles. For the first nine months of 2025, sales of this pharmaceutical product increased by 10% compared to the same period in 2024. Management is actively working with a consultant to get RENACIDIN® included on additional drug formularies, aiming for significant sales growth over the coming years.

Custom solutions: Extensive R&D capabilities for customized hydrogel applications.

The company's foundation rests on its research-heavy approach. United-Guardian, Inc. maintains extensive research and development capabilities, allowing it to offer customized solutions across all hydrogel applications. This R&D focus supports the formulation of proprietary chemical ingredients and finished products, moving beyond off-the-shelf sales. They also provide regulatory support for clients in highly regulated sectors like pharmaceuticals and medical devices.

Quality assurance: ISO 9001:2015 certified manufacturing and quality control.

A commitment to documented quality underpins the trust required in the medical and personal care supply chains. United-Guardian, Inc. has been certified by DQS Inc. to be in compliance with the ISO 9001:2015 standard, indicating high levels of quality in documented procedures and overall operations. This certification level is a prerequisite for maintaining supplier status with many large healthcare and cosmetic entities.

Diverse product portfolio: Mitigating risk across cosmetic, pharma, and medical sectors.

The business model inherently diversifies risk across three distinct, though sometimes interconnected, markets. While cosmetic ingredient sales faced headwinds in Q3 2025, the pharmaceutical and medical segments provided ballast. Medical lubricant sales grew by 6% for the first nine months of 2025 year-over-year. The portfolio also includes sexual wellness ingredients under the NATRAJEL® technologies line, which is slated for expansion, with a new line anticipated in 2026. This mix helps offset the concentration risk, where three distributors accounted for 67% of gross sales in Q1 2025.

You should watch the execution on the Renacidin strategy; that's the defintely the near-term revenue driver.

• Pharmaceutical sales grew 10% (9M 2025 vs 9M 2024).
• Medical product sales grew 6% (9M 2025 vs 9M 2024).
• Q3 2025 Net Income was $268,441, down from $865,484 in Q3 2024.
• The company declared and paid dividends totaling $2,756,323 in 2024.
• Total assets were reported at $12.18 million as of the Q3 2025 report date.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Relationships

You're looking at how United-Guardian, Inc. (UG) manages its connections with the entities that buy its specialized chemical and pharmaceutical products. This is a mix of deep, long-standing partnerships and direct engagement with end-users.

Long-term B2B relationships: United-Guardian, Inc. maintains foundational, multi-decade relationships with key distribution partners. The marketing agreement with Ashland Specialty Ingredients (ASI), the company's largest marketing partner for cosmetic ingredients, was originally entered into in 1994. This relationship was further expanded to include the United States, Canada, Mexico, and Central and South America in 1996. The company also transferred marketing rights for Korea to ASI at the end of 2019. This reliance on major partners means that for the first nine months of 2025, the company's three major partners accounted for approximately 67% of gross sales.

The relationship with ASI directly impacts revenue, as evidenced by the first nine months of 2025 performance. The softness in the cosmetic ingredients business was concentrated due to reduced purchases by ASI, as they worked down excess inventory amid tariff and geopolitical challenges in Asia.

The distribution reliance is quantified in recent sales figures related to ASI:

Metric	Period Ending September 30, 2021	Period Ending December 31, 2020
Sales to ASI as % of Total Company Sales	Approximately 40%	Approximately 29%
% of ASI Sales to Foreign Countries (based on ASI data)	74%	68%

Dedicated distributor support: United-Guardian, Inc. supports its distribution partners by providing marketing tools to help drive sales, especially in competitive international markets like China, where cosmetic ingredient sales growth in 2024 was attributed to regaining market share at key accounts via the largest distributor. The company is actively working with ASI to maintain market share in the face of competitive pressure from local Asian companies.

Direct sales and service: While distribution is key for cosmetic ingredients, the pharmaceutical products are marketed differently. United-Guardian, Inc.'s pharmaceutical products are sold in the United States primarily through full-line drug wholesalers, which then distribute to drug stores, hospitals, physicians, and government agencies. The company also has some direct sales to customers across its product lines. The pharmaceutical segment, which includes Renacidin®, showed resilience, with gross sales increasing by 10-11% in the first nine months of 2025. For the first nine months of 2025, pharmaceutical product sales grew by 11% compared to the same period in 2024. Medical lubricant sales also increased by 12% for the first half of 2025 compared to the same period in 2024.

Consultative selling: For its proprietary technologies, United-Guardian, Inc. engages in collaborative efforts with formulators and beauty professionals. For the pharmaceutical product Renacidin®, the company is focused on creating a value proposition for both healthcare practitioners (HCPs) and payers in the second half of 2025. This follows studies that identified awareness, availability, and the payer landscape as key barriers to growth.

The company's focus on its core product lines shows clear segment performance as of the latest reporting:

• Pharmaceutical product sales increased by 10% over the first nine months of 2025 compared to the same period in 2024.
• Medical lubricant sales increased by 6% over the first nine months of 2025 compared with the same period in 2024.
• Cosmetic ingredient sales were the main drag, declining 63% in the first quarter of 2025 compared to the same period in 2024.

Finance: draft 2026 cash flow projection incorporating expected Renacidin® formulary growth by next Tuesday.

United-Guardian, Inc. (UG) - Canvas Business Model: Channels

You're looking at how United-Guardian, Inc. (UG) gets its products to market as of late 2025. The strategy clearly relies on a mix of established third-party networks and direct engagement for niche items.

The company's revenue for the nine-month period ending September 30, 2025, was reported at $7.58 million, a decrease from $9.71 million in the same period of 2024. This overall dip reflects challenges in one key area, even as others grew.

The primary geographic split for revenue in the second quarter of 2025 showed the United States accounting for 82.68% of sales, with Non-US markets making up the remaining 17.32%.

Here is a look at the performance metrics tied to the different product categories that flow through these channels, based on the first nine months of 2025 compared to the first nine months of 2024:

Product/Segment (Channel Proxy)	Growth (9M 2025 vs 9M 2024)	9M 2025 Revenue Contribution (Approximate)
Pharmaceutical Products (Wholesalers)	Increased by 10%	51.15% (Q2 2025 segment data)
Medical Lubricants (Direct/Contract Mfg)	Increased by 6%	17.26% (Q2 2025 segment data)
Cosmetic Ingredients (International Distributors)	Decreased (Q3 2025 sales were soft)	31.59% (Q2 2025 segment data)

International distributors: For cosmetic ingredients, like ASI and Azelis Group NV.

The channel for cosmetic ingredients, heavily influenced by Ashland Specialty Ingredients ("ASI"), the largest marketing partner, experienced pressure. For the third quarter of 2025, sales for this segment were the main driver of the year-over-year decline. Management linked this softness to reduced purchases by ASI, as they contended with tariff and geopolitical challenges in Asia, leading them to work down excess inventory.

• Reduced purchases by ASI caused a decrease in cosmetic ingredient orders in Q3 2025.
• ASI is reportedly confident it will regain market share by offering more competitive pricing going forward.

Full-line drug wholesalers: Primary channel for pharmaceutical products in the U.S.

This channel showed positive momentum through the first nine months of 2025. Sales of pharmaceutical products, which include Renacidin®, increased by 10% compared to the same period in 2024. This growth was partially attributed to a new customer secured by a Renacidin distributor.

Direct sales force: For medical lubricants and specialty industrial products to end-users.

Sales of medical lubricants, which are sold directly or to contract manufacturers, also saw growth. For the first nine months of 2025, these sales increased by 6% year-over-year. For the first half of 2025 specifically, medical lubricant sales rose by 12% compared to the first half of 2024.

Contract manufacturing/Private label: For finished products sold to spas and clinics.

Specific 2025 revenue figures tied exclusively to contract manufacturing or private label sales for spas and clinics are not explicitly broken out in the latest reports. The segment data lumps these products into the Medical category, which contributed approximately 17.26% of Q2 2025 revenue.

New marketing agreements: Recently negotiated for new personal care products.

Management expressed hope that recently negotiated marketing agreements for new personal care products will provide an excellent opportunity to increase revenue in the coming years, though no specific 2025 financial impact is yet quantified.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Segments

You're looking at the core customer base for United-Guardian, Inc. (UG) as of late 2025. Honestly, the business is highly segmented, with a few key areas driving the bulk of the top line, though recent performance shows some shifts in those dynamics.

Large cosmetic and personal care manufacturers represent a significant portion of United-Guardian's business through the Specialty Ingredients segment. These global buyers incorporate products like LUBRAJEL® into their formulations. For the quarter ended June 25, 2025, this segment accounted for 31.59% of the company's revenue. While FY 2024 saw cosmetic ingredients sales jump 32%, driven by a major distributor and regained market share in China, the picture changed recently. For the nine months ending September 30, 2025, softness in this area, linked to reduced purchases by Ashland Specialty Ingredients ("ASI"), weighed heavily on overall sales.

The U.S. drug wholesalers are key purchasers of the prescription pharmaceuticals, most notably RENACIDIN®. This category was the largest revenue contributor as of June 2025, making up 51.15% of the total revenue. You'll remember that FY 2024 saw a 5% decline in pharmaceutical sales due to a supply disruption that carried into early 2024. Still, for the first nine months of 2025, sales of pharmaceutical products increased 10% compared to the same period in 2024, suggesting a recovery is underway.

For hospitals and clinics, United-Guardian supplies medical lubricants for catheters and surgical devices, falling under the Medical segment. This segment represented 17.26% of revenue as of June 2025. Medical lubricants sales saw a strong 16% increase in FY 2024. Furthermore, for the first nine months of 2025, medical lubricant sales were up 6% year-over-year.

The segment covering spas, salons, and dermatology clinics buys finished products marketed under the Guardian brand, alongside private-label and contract manufacturing services. This falls under the Finished Products segment. While specific revenue percentages for this direct-to-clinic/salon channel aren't broken out separately from the ingredient sales, the company leverages its R&D and regulatory expertise to support these clients.

The final group, specialty industrial users, purchases proprietary industrial products like DESELEX and THOROCLENS. Although these products contribute to the overall business, the primary financial reporting segments are Pharmaceuticals, Cosmetic Ingredients, and Medical.

Here's a quick look at how the main revenue streams stacked up based on the latest segment data we have:

Customer Group/Segment	Primary Product Example	Revenue Share (as of Jun 2025)	FY 2024 Sales Growth
U.S. Drug Wholesalers	RENACIDIN® (Pharmaceuticals)	51.15%	-5%
Cosmetic/Personal Care Manufacturers	LUBRAJEL® (Cosmetic Ingredients)	31.59%	+32%
Hospitals/Clinics (Medical)	Medical Lubricants	17.26%	+16%

You should keep an eye on the concentration risk here. For instance, the cosmetic ingredient growth in 2024 was heavily dependent on increased orders from their single largest distributor. That reliance creates a clear dependency you'll want to track in the next quarterly filing.

Focusing on the recent nine-month performance for 2025 versus 2024 gives you a near-term view of customer purchasing trends:

• Pharmaceutical products sales increased 10%.
• Medical lubricants sales increased 6%.
• Cosmetic ingredients sales were the main driver of the year-over-year sales decline in Q3 2025.

The company's total net sales for the quarter ending September 30, 2025, were $2.26 million, which was a 26% drop from the prior year's quarter. For the first nine months of 2025, net sales were $7.58 million, down 22% from the first nine months of 2024.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Cost Structure

You're looking at the cost side of United-Guardian, Inc. (UG) operations as of late 2025. This is where the money actually goes to keep the lights on and the products moving out of the Hauppauge, New York facility.

Manufacturing and production costs: Raw materials, labor, and overhead for the New York facility

The costs tied directly to making the cosmetic ingredients, medical lubricants, and pharmaceuticals are captured in the Cost of Sales line item. For the second quarter of 2025, the Cost of Sales totaled $1,340,854. This represented 47% of the quarter's net sales. Looking at the first half of 2025, the total Cost of Sales was $2,463,930, which was lower than the $3,117,580 reported for the same period in 2024. Peter A. Hiltunen, Senior Vice President of Production & Procurement, oversees the efficiency of sourcing raw materials and managing the production floor.

Operating expenses: Increased in 2025, including higher payroll and general operating costs

General operating costs have been a point of focus, contributing to the pressure on income from operations in Q3 2025. For the second quarter of 2025, Operating Expenses were reported at $694,050, marking an increase of 15% compared to the $602,777 recorded in the second quarter of 2024. For the first six months of 2025, Total Operating Expenses reached $1,326,785, up from $1,171,642 in the first half of 2024. Research and development expense, which is part of the overall operating structure, was $107,868 in Q2 2025.

Here's a quick look at the key expense components for Q2 2025 versus the prior year:

Expense Category	Q2 2025 Amount (USD)	Q2 2024 Amount (USD)
Cost of Sales	1,340,854	1,561,090
Operating expenses	694,050	602,777
Research and development expense	107,868	111,660

Distribution and marketing costs: Supporting domestic and international distribution partners

United-Guardian, Inc. distributes products through a network of domestic and international partners. While specific line-item figures for distribution and marketing aren't broken out separately in the readily available summaries, these activities are embedded within the overall operating expenses. The company relies on its largest cosmetic distributor, Ashland Specialty Ingredients (ASI), though their reduced purchases impacted Q2 2025 sales.

Regulatory and compliance costs: Maintaining FDA approvals and ISO certification

The company leverages its in-house regulatory expertise to support product formulation, testing, and compliance with industry standards, including maintaining FDA approvals and ISO certification. These compliance efforts are a necessary, ongoing cost factored into the general operating structure, supporting the pharmaceutical and medical lubricant segments.

Dividend payments: A consistent strategy, with a Q1 2025 dividend of $0.35 per share

United-Guardian, Inc. maintains a consistent strategy of returning value to shareholders. The Board declared a cash dividend of $0.35 per share in Q1 2025, paid on February 18, 2025, marking the 30th consecutive year of dividend payments. Subsequently, a cash dividend of $0.25 per share was declared in July 2025, payable August 1, 2025. This results in an estimated total annual dividend for 2025 of $0.60 per share. The Q1 2025 dividend payment represented a net cash use of $1,607,893 in financing activities for that period.

The dividend history for the first half of 2025 looks like this:

• Q1 2025 Dividend: $0.35 per share.
• Q2/H1 2025 Dividend Declared: $0.25 per share.
• Total Estimated 2025 Annual Dividend: $0.60.

The Board balanced shareholder returns with retaining earnings for growth initiatives.

United-Guardian, Inc. (UG) - Canvas Business Model: Revenue Streams

You're looking at the core ways United-Guardian, Inc. (UG) brings in money as of late 2025. The revenue picture shows a clear reliance on the pharmaceutical side, even as the cosmetic ingredient business faces near-term headwinds.

The total top-line number for the first nine months of 2025 gives you the big picture:

• Total net sales for the nine-month period ended September 30, 2025, totaled $7,583,613.

Here's how the revenue streams broke down by percentage based on the second quarter of 2025 figures:

Revenue Stream	Q2 2025 Revenue Share
Pharmaceutical product sales	51.15%
Cosmetic ingredient sales	31.59%
Medical lubricant sales	17.26%

Drilling down into the performance trends for the first nine months of 2025 versus the prior year shows where the growth and the pressure points are:

• Pharmaceutical product sales: Generated 51.15% of Q2 2025 revenue, with sales for the first nine months of 2025 up 10% compared to the same period in 2024.
• Medical lubricant sales: Accounted for 17.26% of Q2 2025 revenue, and sales for the first nine months of 2025 were up 6% year-over-year.
• Cosmetic ingredient sales: Made up 31.59% of Q2 2025 revenue, but sales are down year-over-year, specifically experiencing a decrease in the third quarter compared with 2024. This was attributable primarily to reduced purchases by Ashland Specialty Ingredients ("ASI"), United-Guardian's largest marketing partner.

The final stream involves the finished goods business. This is where United-Guardian, Inc. directly markets its own consumer-facing products.

• Finished product/private label sales: This revenue comes from Guardian brand products marketed for esthetic markets, which includes providing private-label and contract manufacturing services to spas, salons, and dermatology clinics.

The company is definitely leaning on its pharmaceutical segment for stability right now. Finance: draft the 13-week cash flow view by Friday.